NASDAQ:DMPI - DelMar Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DelMar Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.62 +0.05 (+8.73 %) (As of 12/6/2019 04:00 PM ET) Add Compare Today's Range$0.59Now: $0.62▼$0.6450-Day Range$0.49MA: $0.68▼$1.0552-Week Range$0.40Now: $0.62▼$6.29Volume218,044 shsAverage Volume436,090 shsMarket Capitalization$7.10 millionP/E RatioN/ADividend YieldN/ABeta1.34 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DMPI Previous Symbol CUSIPN/A CIK1498382 Webhttp://www.delmarpharma.com/ Phone858-350-4364Debt Debt-to-Equity RatioN/A Current Ratio6.24 Quick Ratio6.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.13) per share Price / Book-0.55Profitability EPS (Most Recent Fiscal Year)($3.16) Net Income$-8,050,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-162.28%Miscellaneous Employees4 Outstanding Shares11,399,000Market Cap$7.10 million Next Earnings Date2/10/2020 (Estimated) OptionableNot Optionable Receive DMPI News and Ratings via Email Sign-up to receive the latest news and ratings for DMPI and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:DMPI Rates by TradingView DelMar Pharmaceuticals (NASDAQ:DMPI) Frequently Asked Questions What is DelMar Pharmaceuticals' stock symbol? DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI." When did DelMar Pharmaceuticals' stock split? How did DelMar Pharmaceuticals' stock split work? DelMar Pharmaceuticals shares reverse split on the morning of Wednesday, May 8th 2019. The 1-10 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 7th 2019. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. How were DelMar Pharmaceuticals' earnings last quarter? DelMar Pharmaceuticals Inc (NASDAQ:DMPI) issued its quarterly earnings data on Tuesday, September, 10th. The company reported ($0.89) EPS for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.59. View DelMar Pharmaceuticals' Earnings History. When is DelMar Pharmaceuticals' next earnings date? DelMar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 10th 2020. View Earnings Estimates for DelMar Pharmaceuticals. What is the consensus analysts' recommendation for DelMar Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DelMar Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DelMar Pharmaceuticals. Has DelMar Pharmaceuticals been receiving favorable news coverage? Headlines about DMPI stock have been trending very positive on Saturday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. DelMar Pharmaceuticals earned a coverage optimism score of 3.6 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for DelMar Pharmaceuticals. Are investors shorting DelMar Pharmaceuticals? DelMar Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 241,800 shares, an increase of 270.3% from the October 31st total of 65,300 shares. Based on an average trading volume of 568,300 shares, the days-to-cover ratio is presently 0.4 days. Approximately 9.9% of the shares of the company are sold short. View DelMar Pharmaceuticals' Current Options Chain. Who are some of DelMar Pharmaceuticals' key competitors? Some companies that are related to DelMar Pharmaceuticals include Q BioMed (QBIO), Aptevo Therapeutics (APVO), Innovate Biopharmaceuticals (INNT), Provectus Biopharmaceuticals (PVCT), Kazia Therapeutics (KZIA), ContraFect (CFRX), Eyegate Pharmaceuticals (EYEG), Soligenix (SNGX), ProPhase Labs (PRPH), OncoSec Medical (ONCS), Melinta Therapeutics (MLNT), Acerus Pharmaceuticals (TRLPF), Bio-Path (BPTH), Aerpio Pharmaceuticals (ARPO) and Unum Therapeutics (UMRX). What other stocks do shareholders of DelMar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other DelMar Pharmaceuticals investors own include Advanced Micro Devices (AMD), Sunworks (SUNW), Medical Properties Trust (MPW), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), BIOLINERX LTD/S (BLRX), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX). Who are DelMar Pharmaceuticals' key executives? DelMar Pharmaceuticals' management team includes the folowing people: Mr. Saiid Zarrabian B.Sc., MBA, Pres, CEO & Director (Age 66)Mr. Jeffrey A. Bacha, Founder (Age 51)Dr. Dennis M. Brown, Co-Founder & Chief Scientific Officer (Age 69)Mr. Scott Praill CA, CPA, BSc, CFO & Sec. (Age 52) Who are DelMar Pharmaceuticals' major shareholders? DelMar Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (8.35%). View Institutional Ownership Trends for DelMar Pharmaceuticals. Which major investors are buying DelMar Pharmaceuticals stock? DMPI stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for DelMar Pharmaceuticals. How do I buy shares of DelMar Pharmaceuticals? Shares of DMPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is DelMar Pharmaceuticals' stock price today? One share of DMPI stock can currently be purchased for approximately $0.62. How big of a company is DelMar Pharmaceuticals? DelMar Pharmaceuticals has a market capitalization of $7.10 million. The company earns $-8,050,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. DelMar Pharmaceuticals employs 4 workers across the globe.View Additional Information About DelMar Pharmaceuticals. What is DelMar Pharmaceuticals' official website? The official website for DelMar Pharmaceuticals is http://www.delmarpharma.com/. How can I contact DelMar Pharmaceuticals? DelMar Pharmaceuticals' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-350-4364 or via email at [email protected] MarketBeat Community Rating for DelMar Pharmaceuticals (NASDAQ DMPI)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 246 (Vote Outperform)Underperform Votes: 254 (Vote Underperform)Total Votes: 500MarketBeat's community ratings are surveys of what our community members think about DelMar Pharmaceuticals and other stocks. Vote "Outperform" if you believe DMPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMPI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/7/2019 by MarketBeat.com StaffFeatured Article: What does it mean to hold a stock in street name?